{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:53:04Z","timestamp":1777420384734,"version":"3.51.4"},"reference-count":37,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the published data including the pharmacology, efficacy, and safety of seladelpar, a peroxisome proliferator-activated receptor delta (PPAR\u03b4) agonist leading to the Food and Drug Administration (FDA) accelerated approval for the treatment of primary biliary cholangitis (PBC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources:<\/jats:title>\n                    <jats:p>A PubMed (January 1, 1985 to January 27, 2025) literature search was performed using the terms seladelpar, MBX-8025, peroxisome proliferator-activated receptor agonist, and PBC. Other data sources included Google Scholar and the National Institutes of Health Clinical Trials Registry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection and data extraction:<\/jats:title>\n                    <jats:p>All English-language literature evaluating the pharmacology, pharmacokinetics, safety, and efficacy of seladelpar in the treatment of PBC was reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis:<\/jats:title>\n                    <jats:p>Seladelpar is the first PPAR\u03b4 agonist in the treatment of PBC that has shown a significant reduction across biochemical response, alkaline phosphatase (ALP) normalization, and pruritus as compared to placebo while demonstrating safety and tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to patient care and clinical practice in comparison to existing drugs:<\/jats:title>\n                    <jats:p>While existing drug treatments for PBC are efficacious, there remains an unmet need due to an incomplete biochemical response in many patients. Patients frequently suffer from symptoms, including pruritus, impacting their quality of life. Seladelpar could have a beneficial role in PBC as add-on therapy in improving biochemical response as well as alleviating pruritus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Seladelpar is a safe and effective treatment for PBC and fills a significant unmet need. Seladelpar\u2019s clinical benefit predicted by improvement in surrogate endpoints may need confirmation for traditional FDA approval.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280251320069","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T08:12:47Z","timestamp":1741767167000},"page":"951-958","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Seladelpar for the Treatment of Primary Biliary Cholangitis"],"prefix":"10.1177","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6764-5263","authenticated-orcid":false,"given":"Adonice P.","family":"Khoury","sequence":"first","affiliation":[{"name":"Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Gainesville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0902-5031","authenticated-orcid":false,"given":"Jason","family":"Powell","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Gainesville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01303-5"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2023.22239"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.02.005"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30145"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15039"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.04.001"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-024-02460-0"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2130750"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30246-7"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.07.061"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","unstructured":"Silveira MG Brunt EM Heathcote J Gores GJ Lindor KD Mayo MJ. American association for the study of liver diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology. 2010;52(1):349-359. doi:10.1002\/hep.23637","DOI":"10.1002\/hep.23637"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells13181580"},{"key":"e_1_3_2_15_2","unstructured":"Ipsen\u2019s Iqirvo\u00ae receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis. United States. Accessed January 23 2024. https:\/\/www.ipsen.com\/us\/press-releases\/ipsens-iqirvo-receives-u-s-fda-accelerated-approval-as-a-first-in-class-ppar-treatment-for-primary-biliary-cholangitis\/"},{"key":"e_1_3_2_16_2","unstructured":"FDA. Gilead\u2019s Livdelzi seladelpar granted accelerated approval for primary biliary cholangitis by U.S. Accessed October 23 2024. https:\/\/www.gilead.com\/news\/news-details\/2024\/gileads-livdelzi-seladelpar-granted-accelerated-approval-for-primary-biliary-cholangitis-by-us-fda"},{"key":"e_1_3_2_17_2","unstructured":"U.S. Food and Drug Administration. Accelerated approval program. FDA. Published February 21 2024. Accessed October 18 2024. https:\/\/www.fda.gov\/drugs\/nda-and-bla-approvals\/accelerated-approval-program"},{"key":"e_1_3_2_18_2","unstructured":"Gilead Sciences Inc. Livdelzi [package insert]. Gilead Sciences Inc.;2024. Accessed October 18 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217899s000lbl.pdf"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2023.100188"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1061"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312100"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000395"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)30688-3"},{"key":"e_1_3_2_24_2","unstructured":"Mao Z Martin R Steinberg A et al Pharmacokinetics safety and tolerability of seladelpar in subjects with hepatic impairment [FRI-041]. Poster presented at The International Liver Congress; April 12 2019; Vienna Austria. Accessed October 24 2024. https:\/\/www.postersessiononline.eu\/173580348_eu\/congresos\/ILC2019\/aula\/-FRI_41_ILC2019.pdf"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.02.033"},{"key":"e_1_3_2_26_2","unstructured":"Gilead Sciences. ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC). Clinicaltrials.gov; 2024. Accessed October 31 2024. https:\/\/clinicaltrials.gov\/study\/NCT03301506."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17755"},{"key":"e_1_3_2_28_2","unstructured":"HCP Live. Seladelpar NDA submitted to FDA for primary biliary cholangitis. Published December 15 2023. Accessed October 29 2024. https:\/\/www.hcplive.com\/view\/seladelpar-nda-submitted-to-fda-for-primary-biliary-cholangitis"},{"key":"e_1_3_2_29_2","unstructured":"Trivedi P Levy C Kowdley KV et al Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis (PBC): interim results for 2 years from the ASSURE study. Poster presented at the European Association for the Study of the Liver Congress; June 5 2024; Milan Italy. Accessed October 19 2024. https:\/\/d1io3yog0oux5.cloudfront.net\/_b7276463a55afd8cca9c3c88840e2860\/cymabay\/db\/304\/4087\/pdf\/CYM_EASL_Poster_05242024_v7_Final+LMRC+%281%29.pdf"},{"key":"e_1_3_2_30_2","unstructured":"Gilead Sciences. AFFIRM: A Randomized Double-blind Placebo-controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis. Clinicaltrials.gov; 2024. Accessed October 28 2024. https:\/\/clinicaltrials.gov\/study\/NCT06051617"},{"key":"e_1_3_2_31_2","unstructured":"Gilead Sciences. IDEAL: A 52-Week Double-Blind Placebo-Controlled Randomized Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA). Clinicaltrials.gov; 2024. Accessed October 28 2024. https:\/\/clinicaltrials.gov\/study\/NCT06060665"},{"key":"e_1_3_2_32_2","unstructured":"Watkins P Kleiner D Bedossa P et al An independent blinded review of suspected drug induced liver injury (DILI) in nonalcoholic steatohepatitis (NASH) patients by a panel of pathologists and hepatologists: lessons learned from the seladelpar hepatoxicity review committee (SHRC) [PO-1504]. Presented at The European Association for the Study of the Liver International Liver Congress Virtual; 2021. Accessed November 1 2024. https:\/\/www.postersessiononline.eu\/173580348_eu\/congresos\/ILC2021\/aula\/-PO_1504_ILC2021.pdf"},{"key":"e_1_3_2_33_2","unstructured":"Taylor P. PBC drug choices rise in US with OK for Gilead\u2019s seladelpar. Pharmaphorum. Published August 15 2024. Accessed January 18 2024. https:\/\/pharmaphorum.com\/news\/pbc-drug-choices-rise-us-ok-gileads-seladelpar"},{"key":"e_1_3_2_34_2","unstructured":"FDA. Due to risk of serious liver injury FDA restricts use of Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) patients with advanced cirrhosis. Published June 3 2021. Accessed October 22 2024. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/due-risk-serious-liver-injury-fda-restricts-use-ocaliva-obeticholic-acid-primary-biliary-cholangitis"},{"key":"e_1_3_2_35_2","unstructured":"Intercept Pharmaceuticals Inc. Ocaliva [package insert]. Intercept Pharmaceuticals Inc.; 2022. Accessed November 1 2024. https:\/\/www.interceptpharma.com\/wp-content\/uploads\/2023\/08\/Ocaliva_USPI_Clean_VV-REG-040954.pdf"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32117"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)30688-3"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.06.009"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251320069","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280251320069","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251320069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:01Z","timestamp":1777374841000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280251320069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/10600280251320069"],"URL":"https:\/\/doi.org\/10.1177\/10600280251320069","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]}}}